# A Study to Evaluate the Safety, Tolerability and Pharmacokinetics and Pharmacodynamics of RO7062931in Healthy Volunteers and Subjects With Chronic Hepatitis B

> **NCT03038113** · PHASE1 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 119 (actual)

## Conditions studied

- Chronic Hepatitis B

## Interventions

- **DRUG:** RO7062931
- **DRUG:** Placebo
- **DRUG:** Immune Modulator

## Key facts

- **NCT ID:** NCT03038113
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-02-06
- **Primary completion:** 2019-10-18
- **Final completion:** 2019-10-18
- **Target enrollment:** 119 (ACTUAL)
- **Last updated:** 2020-12-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03038113

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03038113, "A Study to Evaluate the Safety, Tolerability and Pharmacokinetics and Pharmacodynamics of RO7062931in Healthy Volunteers and Subjects With Chronic Hepatitis B". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03038113. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*